According to FutureWise analysis the market for Hypoparathyroidism Treatment in 2023 was US$ 1.09 billion, and is expected to reach US$ 2.2 billion by 2031 at a CAGR of 8.5%.
Hypoparathyroidism is an endocrine disorder in which the parathyroid glands, which are found in the neck region and do not produce enough parathyroid hormone (PTH). The optimal level of calcium, phosphate, and calcitriol (active Vitamin D) in the blood and bones is crucially maintained by the parathyroid hormone (PTH). A rare endocrine condition called hypoparathyroidism is brought on by inadequate or non-existent parathyroid hormone production. Supplementing the body with vitamins and minerals to balance the levels of calcium and phosphorus in the blood is one of the most prevalent treatments for hypoparathyroidism which includes taking calcium carbonate pills or high doses of vitamin D orally.
When there is not enough PTH, calcium levels drop and phosphorus levels increase, leading to symptoms such as muscle cramps, twitching, and spasms, as well as numbness and tingling in the fingers, toes, and around the mouth. There are several causes of hypoparathyroidism, including genetic mutations, autoimmune disorders, surgery, radiation therapy, or damage to the parathyroid glands due to injury or infection. While there is no permanent cure for hypoparathyroidism, the development of innovative and more effective treatments is likely to improve the lives of those who suffer from this condition. As research continues in this field, we can expect to see new innovations and breakthroughs that will help to improve the diagnosis and treatment of hypoparathyroidism.
FutureWise Market Research has published a report that provides an insightful analysis of Hypoparathyroidism Treatment Market trends that are affecting the overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Hypoparathyroidism-Treatment-Market/11324
Hypoparathyroidism Treatment Market Segmentation:
By Drug Class
- Parathyroid Hormone
- The Path
- Others
- Vitamin D Analogue
- Vitamin D2
- Vitamin D3
- Calcium Supplements
By Route of Administration
- Oral
- Parental
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Sales
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Hypoparathyroidism Treatment Market:
- Shire-NPS Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- EnteraBio Ltd.
- WCCT Global Inc.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
Ask For Discount: https://www.futurewiseresearch.com/contact.aspx?rpt=11324%20type=discount
**Objectives of this Study: **
- To provide a comprehensive analysis of the Hypoparathyroidism Treatment Market By Drug Class, By Route of Administration, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
FutureWise Research
Contact Person: Vinay Thaploo.
Email: sales@futurewiseresearch.com
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com
